A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING PHASE 2 STUDY OF ISIS 678354 ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)

Registry ID: ISIS 678354-CS2
Source registry: HEALTH_CANADA
Status: Ongoing
Phase: PHASE2
Study type: INTERVENTIONAL
Sponsor: AKCEA THERAPEUTICS INC
Start date: 2019-01-02
Last update: 2017-12-06

Conditions

CARDIOVASCULAR DISEASE
HYPERTRIGLYCERIDEMIA

Related clinical trials

A PHASE 2, OPEN-LABEL TRIAL EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF ION775 IN ADULTS WITH HYPERTRIGLYCERIDEMIA
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 (SOLBINSIRAN) IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SOLARIS-1)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PARTICIPANTS WITH ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND/OR CHRONIC KIDNEY DISEASE (ATTAIN-OUTCOMES)
ZENITH: A PHASE 3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZILEBESIRAN IN ADDITION TO STANDARD OF CARE IN REDUCING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULT PATIENTS WITH HYPERTENSION NOT ADEQUATELY CONTROLLED AND WITH EITHER ESTABLISHED CARDIOVASCULAR DISEASE OR HIGH RISK FOR CARDIOVASCULAR DISEASE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF MUVALAPLIN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE HAD A PRIOR ATHEROSCLEROTIC CARDIOVASCULAR EVENT OR ARE AT RISK FOR A FIRST ATHEROSCLEROTIC CARDIOVASCULAR EVENT ¿ MOVE-LP(A)
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE IMPACT OF MARIDEBART CAFRAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN PARTICIPANTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OVERWEIGHT OR OBESITY (MARITIME-CV)

View on source registry